One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Numbers Do Not Lie: The Dire Need for New Directions in IBD
Claudio Fiocchi, Dimitrios Iliopoulos
doi : 10.1093/ecco-jcc/jjac102
Journal of Crohn's and Colitis, Volume 16, Issue 11, November 2022, Pages 1649–1650
Network Analysis of Inflammatory Bowel Disease Research: Towards the Interactome
M Emilia Fernandez, F Nicolas Nazar, Luciana B Moine, Cristian E Jaime, Jackelyn M Kembro, Silvia G Correa
doi : 10.1093/ecco-jcc/jjac059
Journal of Crohn's and Colitis, Volume 16, Issue 11, November 2022, Pages 1651–1662
Modern views accept that inflammatory bowel diseases [IBD] emerge from complex interactions among the multiple components of a biological network known as the ‘IBD interactome’. These diverse components belong to different functional levels including cells, molecules, genes and biological processes. This diversity can make it difficult to integrate available empirical information from human patients into a collective view of aetiopathogenesis, a necessary step to understand the interactome. Herein, we quantitatively analyse how the representativeness of components involved in human IBD and their relationships ha ve changed over time.
Multicriteria Decision Analysis for Updating of Quality Indicators for Inflammatory Bowel Disease Comprehensive Care Units in Spain
Xavier Calvet, Julián Panés, Javier Gallardo-Escudero, Alberto de la Cuadra-Grande, Elena Bartolomé, Laura MarÃn, Fernando de la Portilla, Ester Navarro-Correal, Ana Gutiérrez, Pilar Nos, Ruth Serrano, Miguel ?ngel Casado, Manuel Barreiro-de Acosta, Consensus Group
doi : 10.1093/ecco-jcc/jjac068
Journal of Crohn's and Colitis, Volume 16, Issue 11, November 2022, Pages 1663–1675
Management of inflammatory bowel disease [IBD] is complex and IBD Comprehensive Care Units [ICCUs] facilitate the delivery of quality care to IBD patients. The objective of this study was to update the existing set of quality indicators [QIs] for ICCUs, based on a nationwide quality certification programme carried out in Spain, from a multi-stakeholder perspective and using multicriteria decision analysis [MCDA] methodology.
The Impact of Vedolizumab and Ustekinumab on Articular Extra-Intestinal Manifestations in Inflammatory Bowel Disease Patients: A Real-Life Multicentre Cohort Study
Cara De Galan, Marie Truyens, Harald Peeters, Francisco Mesonero Gismero, Ainara Elorza, Paola Torres, Liv Vandermeulen, Aranzazu Jauregui Amezaga, Rocio Ferreiro-Iglesias, Tom Holvoet, Yamile Zabana, Laia Peries Reverter, Gerard Bryan Gonzales, Jeroen Geldof, Gaëlle Varkas, Martine De Vos, Triana Lobat?n
doi : 10.1093/ecco-jcc/jjac058
Journal of Crohn's and Colitis, Volume 16, Issue 11, November 2022, Pages 1676–1686
Extra-intestinal manifestations are frequently reported in inflammatory bowel diseases. However, data comparing the effect of vedolizumab and ustekinumab on articular extra-intestinal manifestations are limited. The aim here was to evaluate differences in new-onset and the evolution of pre-existing joint extra-intestinal manifestations during both treatments.
Combining Pentoxifylline With Vedolizumab for Crohn’s Disease: Results of a Randomised, Placebo-controlled Pilot Study
Shivali Berera, Stephanie C Ioannou, Diana Morillo, Alejandro M A Mantero, Judith Pignac-Kobinger, Niurka Colina, Ana M Santander, Irina Fernandez, Maria Alejandra Quintero, Jennifer Rodriguez, David H Kerman, Oriana M Damas, Frank Czul, Daniel A Sussman, Maria T Abreu, Amar R Deshpande
doi : 10.1093/ecco-jcc/jjac074
Journal of Crohn's and Colitis, Volume 16, Issue 11, November 2022, Pages 1687–1695
The efficacy of current biologics may be limited by targeting only one pathway. Pentoxifylline [PTX] interferes with tumour necrosis factor [TNF] gene expression. We performed a randomised, placebo-controlled pilot study to determine if PTX plus vedolizumab [VDZ] in patients with Crohn’s disease [CD] is safe and improves response compared with VDZ monotherapy.
Intra-abdominal septic complications after ileocolic resection increases risk for endoscopic and surgical postoperative Crohn’s disease recurrence
Salam P Bachour, Ravi S Shah, Florian Rieder, Taha Qazi, Jean Paul Achkar, Jessica Philpott, Bret Lashner, Stefan D Holubar, Amy L Lightner, Edward L Barnes, Jordan Axelrad, Miguel Regueiro, Benjamin Click, Benjamin L Cohen
doi : 10.1093/ecco-jcc/jjac078
Journal of Crohn's and Colitis, Volume 16, Issue 11, November 2022, Pages 1696–1705
Postoperative recurrence [POR] of Crohn’s disease following ileocolonic resection is common. The impact of immediate postoperative intra-abdominal septic complications [IASC] on endoscopic and surgical recurrence has not been elucidated.
Efficacy, safety and tolerability of oral sulphate tablet for bowel preparation in patients with inflammatory bowel disease: A multicentre randomized controlled study
Kyeong Ok Kim, Eun Young Kim, Yoo Jin Lee, Hyun Seok Lee, Eun Soo Kim, Yun Jin Chung, Byung Ik Jang, Sung Kook Kim, Chang Heon Yang Crohn’s and Colitis Association in Daegu-Gyeongbuk (CCAiD)
doi : 10.1093/ecco-jcc/jjac080
Journal of Crohn's and Colitis, Volume 16, Issue 11, November 2022, Pages 1706–1713
We evaluated the efficacy, safety and tolerability of novel oral sulphate tablets [OSTs] vs 2 L of polyethylene glycol and ascorbate [PEG/Asc] in patients with inflammatory bowel disease [IBD].
Novel Budesonide Suppository and Standard Budesonide Rectal Foam Induce High Rates of Clinical Remission and Mucosal Healing in Active Ulcerative Proctitis: a Randomised, Controlled, Non-inferiority Trial
Wolfgang Kruis, Britta Siegmund, Konrad Lesniakowski, Vladimir Simanenkov, Ludmila Khimion, Marcin Sobon, Glebs Delmans, Svetlana V Maksyashina, Oleg A Sablin, Juris Pokrotnieks, Yuriy Mostovoy, Olena Datsenko, Sayar Abdulkhakov, Andriy Dorofeyev, Olena Levchenko, Olga Alexeeva, Pavel Andreev, Ivan P Kolesnik, Emese Mihaly, Orest Abrahamovych, Malgorzata Baluta, Nataliia Kharchenko, Neshta Viacheslav, Yury Uspenskiy, Michael Vieth, Ralf Mohrbacher, Ralph Mueller, Roland Greinwald
doi : 10.1093/ecco-jcc/jjac081
Journal of Crohn's and Colitis, Volume 16, Issue 11, November 2022, Pages 1714–1724
Proctitis is the least extensive type of ulcerative colitis, for which rectal therapy is rarely studied and is underused. This study evaluated the efficacy, safety, and patient’s preference of a novel formulation of budesonide suppository 4 mg, compared with a commercially available budesonide rectal foam 2 mg, for the treatment of mild to moderate ulcerative proctitis.
Early Intestinal Ultrasound Predicts Intravenous Corticosteroid Response in Hospitalised Patients With Severe Ulcerative Colitis
Johan F K F Ilvemark, Rune Wilkens, Peter Thielsen, Anders Dige, Trine Boysen, Jørn Brynskov, Jacob Tveiten Bjerrum, Jakob Benedict Seidelin
doi : 10.1093/ecco-jcc/jjac083
Journal of Crohn's and Colitis, Volume 16, Issue 11, November 2022, Pages 1725–1734
Our aim was to determine if transabdominal intestinal ultrasound changes after 48 ± 24 h of intravenous corticosteroids can predict treatment outcomes in hospitalised patients with severe ulcerative colitis.
Targeted Assessment of Mucosal Immune Gene Expression Predicts Clinical Outcomes in Children with Ulcerative Colitis
Kathryn Clarkston, Rebekah Karns, Anil G Jegga, Mihika Sharma, Sejal Fox, Babajide A Ojo, Phillip Minar, Thomas D Walters, Anne M Griffiths, David R Mack, Brendan Boyle, Neal S LeLeiko, James Markowitz, Joel R Rosh, Ashish S Patel, Sapana Shah, Robert N Baldassano, Marian Pfefferkorn, Cary Sauer, Subra Kugathasan, Yael Haberman, Jeffrey S Hyams, Lee A Denson, Michael J Rosen
doi : 10.1093/ecco-jcc/jjac075
Journal of Crohn's and Colitis, Volume 16, Issue 11, November 2022, Pages 1735–1750
We aimed to determine whether a targeted gene expression panel could predict clinical outcomes in paediatric ulcerative colitis [UC] and investigated putative pathogenic roles of predictive genes.
CD147 Targeting by AC-73 Induces Autophagy and Reduces Intestinal Fibrosis Associated with TNBS Chronic Colitis
Alessia Butera, Maria Teresa Quaranta, Luca Crippa, Isabella Spinello, Ernestina Saulle, Nazzareno Di Carlo, Doriana Campanile, Monica Boirivant, Catherine Labbaye
doi : 10.1093/ecco-jcc/jjac084
Journal of Crohn's and Colitis, Volume 16, Issue 11, November 2022, Pages 1751–1761
Intestinal fibrosis is a common complication of inflammatory bowel diseases. Medical treatment of intestinal fibrosis is an unmet therapeutic need. CD147 overexpression can induce myofibroblast differentiation associated with extracellular matrix deposition, favouring the development of fibrosis. To understand whether CD147 may promote intestinal fibrosis, we analysed its expression and blocked its function by using its specific inhibitor AC-73 [3-{2-[([1,1’-biphenyl]-4-ylmethyl) amino]-1-hydroxyethyl} phenol] in the murine TNBS [trinitrobenzenesulfonic acid]-chronic colitis model associated with intestinal fibrosis.
Aberrant Mesenteric Adipose Extracellular Matrix Remodelling is Involved in Adipocyte Dysfunction in Crohn’s Disease: The Role of TLR-4-mediated Macrophages
Lugen Zuo, Jing Li, Xiaofeng Zhang, Zhijun Geng, Xue Song, Yueyue Wang, Sitang Ge, Ruohan Shi, Yueqing Zhou, Yuanyuan Ge, Rong Wu, Jianguo Hu
doi : 10.1093/ecco-jcc/jjac087
Journal of Crohn's and Colitis, Volume 16, Issue 11, November 2022, Pages 1762–1776
Hypertrophic mesenteric adipose tissue [htMAT] is involved in the disease progression of Crohn’s disease [CD] through expressing proinflammatory adipokines from dysfunctional adipocytes by unknown mechanism. Adipocyte function is affected by dynamic adipose tissue extracellular matrix [ECM] remodelling that is mainly mediated by macrophages, and our study aimed to reveal whether aberrant ECM remodelling was present in CD-htMAT and its effects on adipocyte dysfunction, as well as the mechanism.
Faecal Metabolomics in Paediatric Inflammatory Bowel Disease: A Systematic Review
Jasmijn Z Jagt, Charlotte M Verburgt, Ralph de Vries, Nanne K H de Boer, Marc A Benninga, Wouter J de Jonge, Johan E van Limbergen, Tim G J de Meij
doi : 10.1093/ecco-jcc/jjac079
Journal of Crohn's and Colitis, Volume 16, Issue 11, November 2022, Pages 1777–1790
Paediatric inflammatory bowel disease [IBD] is characterized by altered immunological and metabolic pathways. Metabolomics may therefore increase pathophysiological understanding and could develop into characterization of biomarkers for diagnosis and IBD treatment response. However, no uniform metabolomic profiles have been identified to date. This systematic review aimed to identify faecal metabolomic signatures in paediatric IBD vs controls, and to describe metabolites associated with disease activity and treatment response.
Withdrawn: Expression of Concern
doi : 10.1093/ecco-jcc/jjab227
Journal of Crohn's and Colitis, Volume 16, Issue 11, November 2022, Page 1791
Letter to the Editor
doi : 10.1093/ecco-jcc/jjab225
Journal of Crohn's and Colitis, Volume 16, Issue 11, November 2022, Pages 1792–1793,
